Navigation Links
New study: Incidence and mortality of PCa after termination of PSA-based screening

Milan, 15 March 2013 - Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test, according to the results of a new study to be presented at the 28th Annual EAU Congress in Milan

A joint Swedish-UK study aimed to examined the risk of developing prostate cancer after last invitation to screening. This investigation follows up on previous publication from the Gteborg randomized screening trial (part of ERSPC) by the same group which showed that biennial PSA screening lowered PC mortality with 44%

In the course of the study, which launched in 1995, 20000 men were randomized and 9 952 have been invited every second year for PSA testing while 9952 were randomized to a control arm. All cases of prostate cancer in the screening (n= 6449) as well as the control arm (n= 6974) after reaching the upper age limit for invitation (median 69 range 67-71 years) were identified by matching with the Regional Cancer Register in western Sweden.

For all deaths in men with prostate cancer, a review of cause of death was performed by an independent committee, the date of follow-up being 30 June 2012 or at a maximum of 12 years. PCs diagnosed were classified into low, intermediate or high/advanced risk groups and all attendees were defined as participating at least once

In the course of the study, a total of 173 men with were diagnosed with prostate cancer in the invited arm (with a median follow-up of 4.8 years) and 371 were diagnosed in the control arm (with a median follow-up of 4.9 years).

Up to 9 years after last invitation all risk groups were more commonly diagnosed in the control arm but after 9 years the rates in the screening arm caught up, other than those for the low risk group. In the invited arm, non-attendees had an incidence similar to that of the control arm. Also mortality in PC was lower in the screening arm up to 9 years, which is approximately 50 % of that in the control arm, after termination of screening. At the same time, in the interval of 9-12 years, the screening group had a similar mortality rate to the control.


Contact: Ivanka Moerkerken
European Association of Urology

Related medicine news :

1. Study: Smoking Increases HPV Risks; polyDNA Recommends Gene-Eden-VIR Against HPV
2. Omega XL Reports New Independent Study: Omega-3s Can Boost Children’s IQ
3. Study: 15% of Children Ages 10 - 14 Consider Using Steroids; polyDNA Recommends Muxscle for Safe Muscle Building
4. Study: Dynamic new software improves care of aging brain
5. Bel Marra Health Reports on a New Study: Female Obesity Could Be Due to Less Participation in Household Tasks
6. Study: Steroid Abuse in Teens is Increasing; polyDNA Recommends Muxscle for Safe Muscle Building
7. Study: Catheter-based varicose vein treatments more cost-effective
8. Penn study: Financial incentives affect prostate cancer treatment patterns
9. Study: Mega Vitamins Wont Help After Heart Attack, Chelation Treatment Might
10. Study: Diabetic medication may protect patients from developing heart failure
11. Doctors Health Press Reports on German Study: Only 20% of Patients Get Colonoscopies, Important in Preventing and Diagnosing Colon Cancer
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... 2015 , ... Ministers, senior government and UN agencies, representatives ... of Excellence, and public R&D institutions, civil societies and other partners gathered today ... African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day ...
(Date:11/25/2015)... TX (PRWEB) , ... November 25, 2015 , ... For ... the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two ... services to aid in MAP International’s cause. , MAP International was founded in 1954 ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview ... the country to celebrate their sobriety and show through pictures what a positive ... after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY ... products, continues to provide evidence demonstrating the accuracy of ... World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease ... that both the Company,s GLUCOCARD ® 01 meter ... high accuracy requirements. The ability to accurately measure glucose ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
(Date:11/25/2015)... Ohio , Nov. 25, 2015 ... handle hazardous drug preparations (e.g. pharmacists, pharmacy technicians, ... and veterinary technicians). The chapter also covers all ... drugs (e.g., pharmacies, hospitals, other healthcare institutions, patient ... --> --> ...
Breaking Medicine Technology: